Biotech | Pharma Company | Type/Product Area | Amount | Terms/Details (Month) |
Company** | (Symbol/Country) | |||
(Country) | ||||
I. MODIFIED AGREEMENTS | ||||
Alexion | United States | Modification of 8/95 | $6.5M | U.S. Surgical made additional |
Pharmaceuticals | Surgical Corp. | agreement on trans- | (equity; | $3M equity investment; U.S. |
Inc. | (NYSE:USS) | genic pig organs for | % ND) | Surgical gets exclusive license to |
human transplants | an additional patent application | |||
on method for creating transgenic | ||||
livestock; Alexion also transferred | ||||
certain xenograft manufacturing as- | ||||
sets to U.S. Surgical for $3.5M (10/97) | ||||
BioTransplant | Novartis Pharma | Expansion of 1991 | $36M | Novartis gets worldwide license |
Inc. | AG (Switzerland) | collaboration in xeno- | to mixed bone marrow chimerism | |
transplantation technol- | technology in exchange for license | |||
ogy (which focused on | payments, research funding and | |||
gene therapy approaches) | milestones totaling $36M; agree- | |||
to include BioTransplant's | ment covers 3 additional years; | |||
mixed bone marrow | BioTransplant gets royalties and | |||
chimerism approach | retains co-promotion rights in | |||
for creating specific | North America (10/97) | |||
transplant tolerance | ||||
Cephalon Inc. | TAP Holdings Inc. | Renewal of 5/94 | ND | The parties expanded this agree- |
(U.S.-based joint ven- | collaboration on use | once, in 7/96; TAP is currently | ||
ture between Abbott | of tyrosine kinase | conducting Phase I trials of CEP- | ||
Laboratories and | inhibitors for treating | 2563 and will continue; it will | ||
Takeda Chemical | prostate cancer | also fund R&D for 1 more year | ||
Industries Ltd.; Japan) | (11/97) | |||
CoCensys Inc. | Warner-Lambert | Renewal and expansion | $23.5M | Warner-Lambert will make $7M |
Co. (NYSE:WLA) | of 10/95 agreement on | (equity; | equity investment and pay $16.5M | |
subtype-selective | % ND) | in milestones, as well as royalties; | ||
NMDA receptor antag- | collaboration renewed for 2 years; | |||
onists for treating stroke | CoCensys retains option to parti- | |||
and other central nervous | cipate in U.S. development, com- | |||
system disorders to | mercialization and profit-sharing | |||
include AMPA modula- | (10/97) | |||
tors (another class of | ||||
glutamate receptor) | ||||
Cubist | Merck & Co. Inc. | Expansion of 6/96 | ND | Cubist will continue to conduct |
Pharmaceuticals | (NYSE:MRK) | collaboration on com- | automated screening and lead com- | |
Inc. | pounds that inhibit fun- | pound characterization; Merck will | ||
ction of amino acyl-tRNA | provide additional research funds | |||
synthases for treating drug- | (10/97) | |||
resistant bacteria and fungi | ||||
to include 3 more Cubist | ||||
drug targets and Merck's | ||||
natural products com- | ||||
pound library | ||||
Gensia Sicor Inc. | Sankyo Co. Ltd. | Modification of 4/97 | $7.3M | Gensia Sicor has transferred its |
(Japan) | collaboration on drugs | (8% equity) | pharmaceutical R&D business to | |
for treating Type II | its new subsidiary Metabasis; as | |||
diabetes to include pay- | part of the original agreement be- | |||
ment to Gensia Sicor's | tween Gensia Sicor and Sankyo, | |||
subsidiary Metabasis | Sankyo agreed to equity invest- | |||
Therapeutics Inc. | ment in Gensia Sicor or its subsid- | |||
iary; Sankyo bought $7.25M | ||||
equity in Metabasis Therapeutics | ||||
for an 8% stake (12/97) | ||||
Gliatech Inc. | Janssen Pharma- | Extension of 10/94 | ND | Collaboration was already expanded |
ceutica NV | collaboration on com- | in 1/96, when Janssen increased | ||
(Belgium; subsid- | pounds for Alzheimer's | research funding and milestones | ||
iary of Johnson & | and other neurodegen- | by 50%; currently, Janssen will extend | ||
Johnson; NYSE: | erative diseases, espec- | collaboration for 1 more year and | ||
JNJ) | ially drugs that act as | has retained rights to extend for an | ||
anti-inflammatories | additional year; Janssen will continue | |||
to fund research and pay milestones | ||||
at current levels (10/97) | ||||
ImClone Systems | Merck KGaA | Expansion and amend- | $65.5M | Partners will continue to develop |
Inc. | (Germany) | ment of 12/90 collab- | (equity; | BEC2 for U.S. and international mar- |
oration on therapeutic | % ND) | kets and will comarket in North | ||
cancer vaccines, espec- | America; Merck will continue to have | |||
ially BEC2 anti-idiotypic | exclusive rights elsewhere; Merck | |||
vaccine for use in small | will fund clinical development world- | |||
cell lung cancer and | wide for one indication (partners had | |||
malignant melanoma; | been sharing expenses); ImClone | |||
now includes comar- | will manufacture product; Merck will | |||
keting agreement | pay $15M more in milestones and | |||
will immediately buy $40M in Im- | ||||
Clone convertible preferred stock | ||||
(ImClone will transfer stock in 4 | ||||
tranches, up to 25% in 1st 2 years at | ||||
conversion rate of $12.50 per share; | ||||
the rest converts over 5 years); Merck | ||||
will pay $10M for clinical trial costs and | ||||
ImClone gets $0.5M signing fee (12/97) | ||||
Incyte | Monsanto Co. | Extension of 9/96 | ND | Multi-year partnership; Monsanto |
Pharmaceuticals | (NYSE:MTC) | agreement in plant | gets non-exclusive access to In- | |
Inc. | genomics to provide | cyte's full range of genomic and | ||
Monsanto with a comp- | bioinformatic know-how and ser- | |||
rehensive set of Incyte's | vices for use by all sectors of its life | |||
genomic technologies | sciences business; Incyte could get | |||
future royalties; details ND (10/97) | ||||
Incyte | Pfizer Inc. | Extension of 6/94 | ND | Pfizer will continue to have access |
Pharmaceuticals | (NYSE:PFE) | genomic database | to Incyte's databases, including | |
Inc. | partnership | its LifeSeq gene sequence and | ||
expression database as well as | ||||
others; details ND (12/97) | ||||
Inhale | Baxter Inter- | Renegotiation of certain | ND | Companies are renegotiating terms |
Therapeutic | national Inc. | terms of 3/96 collabora- | due to increase in overall program | |
Systems | (NYSE:BAX) | tion on use of Inhale's | scope and cost (10/97) | |
dry powder pulmonary | ||||
delivery system as tech- | ||||
nology platform for 4 | ||||
Baxter compounds | ||||
LeukoSite Inc. | Warner-Lambert | Expansion of Leuko- | ND | Partners formed multinational |
Co. (NYSE:WLA) | Site's existing agree- | drug discovery alliance and will | ||
and Kyowa Hakko | ments with each partner | combine resources; research col- | ||
Kogyo Ltd.(Japan) | (Warner-Lambert 11/94; | laboration complemented by mar- | ||
Kyowa Hakko 4/97) to | keting agreements (Kyowa Hakko | |||
discover small molecule | is primary marketer in Asia, War- | |||
antagonists that block 4 | ner-Lambert in rest of world); | |||
different chemokine recep- | LeukoSite gets license fees, | |||
tors in leukocytes as treat- | research funding, milestones and | |||
ments for inflammation | royalties (11/97) | |||
and autoimmune diseases | ||||
Microcide | Daiichi Pharma- | Extension of 11/95 | $3.5M | Daiichi will extend collaboration |
Pharmaceuticals | ceutical Co. Ltd. | collaboration on small | for 1 more year and will provide | |
Inc. | (Japan) | molecule drugs to pre- | an extra $3.5M in research support | |
vent antibiotic resistance | (12/97) | |||
in Gram-negative bacter- | ||||
ia (by inhibiting efflux | ||||
pump mechanisms) | ||||
Millennium | Pfizer Inc. | Expansion of 3/95 | ND | Pfizer will add additional research |
Pharmaceuticals | (NYSE:PFE) | collaboration on anti- | personnel to project; further | |
Inc. | fungal drug targets and | details ND (12/97) | ||
leads (which Pfizer init- | ||||
iated with ChemGenics | ||||
Pharmaceuticals Inc., | ||||
since acquired by Millen- | ||||
nium) to include use of | ||||
transcript profiling and | ||||
ultra-high throughput | ||||
screening technologies | ||||
NPS | SmithKline | Extension of 12/93 | $8M | SmithKline extended agreement |
Pharmaceuticals | Beecham plc | research and license | (equity; | for up to 3 years, with additional |
Inc. | (NYSE:SBH; U.K.) | agreement on orally | % ND) | research funding of $2M/year; |
active small molecule | SmithKline also bought $2M in | |||
drugs to treat osteoporo- | stock at premium to market | |||
sis via calcium receptors | (0.16M shares at $12.21/each) and | |||
will buy additional equity annual- | ||||
ly as long as extension remains in | ||||
place; SmithKline will conduct | ||||
clinical trials and market products | ||||
worldwide; NPS gets royalties; | ||||
NPS retains option to co-promote | ||||
in U.S. (12/97) | ||||
OSI | Pfizer Inc. | Continued funding of | $14.3M | Partners will provide Anaderm |
Pharmaceuticals | (NYSE:PFE) | cosmeceuticals joint | with $6.65M in committed fund- | |
Inc. | venture Anaderm | ing through 1998 and $7.6M | ||
Research Corp. (est- | through 1999 (depending on per- | |||
ablished in 1996) | formance); OSI will continue to | |||
and addition of more | own 14% and Pfizer 82% of | |||
targets in skin pigment- | joint venture (12/97) | |||
ation, skin wrinkling | ||||
and hair growth | ||||
Protein Design | Boehringer | Reassignment of product | ND | Boehringer Mannheim returned all |
Labs Inc. | Mannheim GmbH | rights under 10/93 agree- | rights to OST 577 and Protovir | |
(Germany) | ment (with Corange Ltd.) on | and is terminating Phase II trial of | ||
various human and SMART | OST 577 (product gave rise to | |||
antibodies; Boehringer | side effects in some patients); Pro- | |||
is returning rights to 2 | tein Design is evaluating data and | |||
products (OST 577, a human | considering a study combining | |||
anti-hepatitis B antibody; | OST 577 and a nucleoside ana- | |||
and Protovir, a human anti- | logue; Boehringer is retaining | |||
cytomegalovirus antibody) | rights to and continuing develop- | |||
as well as stopping clinical | ment of other 2 products; Roche | |||
development of OST 577; | Holding is in process of acquiring | |||
Boehringer is retaining rights | Corange, Boehringer Mannheim's | |||
and continuing development | parent (pending regulatory appro- | |||
of 2 other products (SMART | val) (12/97) | |||
anti-L-selectin antibody; and | ||||
1 other humanized antibody | ||||
for cardiovascular indications) | ||||
Sequana | Glaxo Wellcome | Intention to renegotiate | ND | Sequana announced this the same |
Therapeutics | plc (NYSE:GLX; | terms of 7/94 alliance | day it announced that it was mer- | |
Inc. | U.K.) | to identify genes involved | ging with Arris Pharmaceutical | |
in Type II diabetes (ex- | Corp.; Sequana and Glaxo will | |||
panded in 2/96 to include | renegotiate the terms of their alli- | |||
obesity) | ance to enable each to retain rights | |||
to gene discoveries made inde- | ||||
pendently and to align collabora- | ||||
tion with each party's strategic | ||||
needs (11/97) | ||||
SIBIA | Eli Lilly and Co. | Lilly exercised option | ND | Lilly exercised option for non- |
Neurosciences | (NYSE:LLY) | (granted in 6/95 exten- | exclusive worldwide fully paid up | |
Inc. | sion of agreement, which | license; Lilly gets right to practice | ||
originally dates from | under patent for internal research | |||
5/92) to license SIBIA's | purposes only and does not have | |||
patent on instrumentation | right to sublicense (11/97) | |||
and assay methods (fluor- | ||||
escense, chemilumines- | ||||
cence) for high through- | ||||
put functional screening | ||||
for new drug leads | ||||
Synaptic | Merck & Co. Inc. | 2nd extension of 11/93 | ND | Merck extended collaboration for |
Pharmaceutical | (NYSE:MRK) | joint research program | 1 more year (1st extension was in | |
Corp. | on drugs for treating be- | 10/96); specific financial terms ND | ||
nign hyperplasia (by block- | (12/97) | |||
ing activation of alpha-1a | ||||
adrenergic receptors) | ||||
Transcend | Boehringer Ingel- | Exercise of option under | ND | Boehringer Ingelheim exercised |
Therapeutics | heim GmbH | 2/97 agreement to devel- | its option to develop product in | |
Inc. | (Germany) | op Procysteine IV (neutral- | Japan, where it will be responsible | |
izes reactive oxygen spe- | for all development and regulatory | |||
cies when drug delivers | expenses as well as marketing, | |||
cysteine to cells) for treat- | sales and distribution; Transcend | |||
ing acute respiratory dis- | gets royalties (12/97) | |||
tress syndrome (currently | ||||
in U.S. Phase III clinical trials) | ||||
Vical Inc. | Merck & Co. Inc. | Expansion of 6/91 licens- | $23M | Merck made $5M equity invest- |
(NYSE:MRK) | ing agreement on Vical's | (equity; | ment at premium to market; Vical | |
naked DNA technology | % ND) | will get $18M in milestones, plus | ||
to make therapeutic vac- | royalties; Vical has certain options | |||
cines for HIV and hepatitis B | to co-promote products in U.S.; | |||
virus (HBV) (1991 agreement | Merck gets exclusive worldwide | |||
covers use in preventive | rights to use technology in therapeu- | |||
vaccines for same viruses) | tic vaccines for HIV and HBV (11/97) | |||
Xenova Group | Suntory Ltd. | Extension of 4/93 | ND | Agreement extended until mid- |
plc (U.K.) | (Japan) | collaboration on fungal | 1998 while Xenova conducts | |
compounds with immuno- | further biological studies on can- | |||
regulatory activity | didate compound; Xenova gets a | |||
milestone payment and continued | ||||
research funding (11/97) | ||||
II. TERMINATED AGREEMENTS | ||||
Agouron | F. Hoffmann-La | Termination of 6/96 | -- | Agouron agreed to end collabora- |
Pharmaceuticals | Roche Ltd. | agreement on 2 anti- | tion and will discontinue develop- | |
Inc. | (Switzerland) | cancer drugs (Thymitaq | ment of Thymitaq (interim results | |
and AG3340, a matrix | of Phase II/III trial demonstrated | |||
metalloproteinase | that drug was not sufficiently su- | |||
inhibitor) and collab- | perior to alternate drugs for liver | |||
oration on early-stage | and head/neck cancer); Roche | |||
anticancer drug develop- | will make final payment and | |||
ment | Agouron will immediately regain all | |||
rights to its anticancer drugs (12/97) | ||||
Alliance | Hoechst Marion | Termination of 3/96 | -- | Hoechst Marion terminated the |
Pharmaceutical | Roussel Inc. (sub- | licensing and develop- | agreement, citing delays in drug | |
Corp. | sidiary of Hoechst | ment agreement on | development and thus higher over- | |
A.G.; Germany) | LiquiVent (biologically | all expenses (12/97) | ||
inert oxygen-carrying | ||||
liquid; a.k.a.perflubron ) | ||||
for treating acute respira- | ||||
tory failure (Phase III | ||||
trial was halted in 4/97 | ||||
due to decrease in mor- | ||||
tality rate for control group) | ||||
Cephalon Inc. | SmithKline Beech- | Termination of 6/93 | -- | Collaboration concluded 12/1/97; |
am plc (NYSE: | collaboration on calpain | all rights related to calpain inhib- | ||
SBH; U.K.) | inhibitors (protease | itors granted under Cephalon pat- | ||
thought to mediate cell | ents will revert to Cephalon; | |||
death) as treatments for | SmithKline is redirecting its re- | |||
stroke | sources to other priorities (11/97) | |||
Cima Labs Inc. | Glaxo Wellcome | Termination of collab- | -- | Companies agreed by mutual con- |
plc (NYSE:GLX; | oration to use Cima's | sent to terminate collaboration | ||
U.K.) | OraSolv drug delivery | (12/97) | ||
technology (microen- | ||||
capsulated drug formu- | ||||
lated into quick-dissolv- | ||||
oral dosage tablet) with | ||||
a Glaxo drug product | ||||
Hyseq Inc. | SmithKline Beech- | Conclusion of 10/95 | -- | Companies have agreed to explore |
am Clinical Labor- | licensing agreement on | ways to commercialize Hyseq's | ||
atories (unit of | Hyseq's DNA sequenc- | technology; this agreement came | ||
SmithKline Beech- | ing-by-hybridization | to term and was not renewed | ||
am plc; NYSE: | technology for use in | (10/97) | ||
SBH; U.K.) | diagnostic tests for | |||
certain genetic diseases | ||||
Megabios Corp. | Pfizer Inc. | Termination of 6/96 | -- | Pfizer decided to discontinue pro- |
(NYSE:PFE) | collaboration on gene | gram with 6 months' notice; there- | ||
therapy products for | fore it will continue funding | |||
inhibiting angiogenesis | through 5/98 (12/97) | |||
in solid tumors | ||||
Protein Polymer | Ethicon Inc. | Termination of 1994 | -- | Ethicon declined to proceed with |
Technologies | (subsidiary of John- | R&D collaboration on | acceptance of specific product | |
Inc. | son & Johnson; | use of genetically engi- | formulation for commercial devel- | |
NYSE:JNJ) | neered protein polymers | opment; Ethicon relinquishes all | ||
as surgical tissue adhes- | rights to technology and has no | |||
ives and sealants for | further financial obligations to | |||
wound closure | Protein Polymer (12/97) | |||
Techniclone | Alpha Therapeutic | Techniclone reacquired | -- | Techniclone will manage further |
Corp. | Corp. (subsidiary | rights to LYM-1 (Oncolym) | clinical development of product; | |
of Green Cross | it licensed to Alpha Thera- | it will make payments to Alpha | ||
Corp.; Japan) | peutic in 10/92 (product | based on milestones; Alpha will | ||
is monoclonal antibody | transfer all clinical data and other | |||
linked to radioactive isotope | information to Techniclone (11/97) | |||
in clinical trials for non- | ||||
Hodgkin's B-cell lymphoma) | ||||
NOTES: | ||||
# This chart contains information on modified and terminated agreements only, covering the time period between 10/1/97 and 12/31/97. It does not include arrangements that are classed strictly as production, marketing and/or distribution agreements, nor does it include any collaborations that involve agricultural product development. | ||||
For a chart listing new collaborations between big pharma and biotech companies for the same time period (10/1/97 - 12/31/97), see the 1/19/98 issue of BioWorld Financial Watch. | ||||
ND = Not disclosed, reported and/or available | ||||
** Unless otherwise noted, the trading symbols for public biotechnology companies can be found by referring to the BioWorld Stock Report For Public Biotechnology Companies on pp. 13-14. |